Biological drugs occupy an increasingly important position in the drug market. Biopharmaceuticals have proven particularly promising in the treatment of non-communicable diseases such as cancer, anemia, and rheumatoid arthritis, and are also applied in vaccines. Most biologics have fewer adverse effects than traditional small-molecule drugs. Glycosylation is a common post-translational modification (PTM) in biopharmaceuticals, which greatly affects the immunogenicity, solubility, and serum half-life of drugs, thereby affecting their efficacy and clinical safety. The analysis of glycosylation in biopharmaceuticals presents obstacles due to the complexity and microheterogeneity of glycoproteins. To overcome the difficulties of drug glycosylation analysis, the biopharmaceutical industry is adopting new techniques to optimize the characterization of glycosylation in drugs. More info : https://www.bioglyco.com/characterization-and-modification-of-drug-glycosylation.html